Effects of pyrrolidine dithiocarbamate on proliferation and nuclear factor-κB activity in autosomal dominant polycystic kidney disease cells by Michelle H. T. Ta et al.
RESEARCH ARTICLE Open Access
Effects of pyrrolidine dithiocarbamate on
proliferation and nuclear factor-κB activity
in autosomal dominant polycystic kidney
disease cells
Michelle H. T. Ta*, David Liuwantara and Gopala K. Rangan
Abstract
Background: Pyrrolidine dithiocarbamate (PDTC) reduces renal cyst growth in a rodent model of polycystic kidney
disease (PKD) but the mechanism of action is not clear. Here, we investigated the hypothesis that PDTC reduces the
proliferation of cystic epithelial cells in vitro in a nuclear factor (NF)-κB-dependent manner.
Methods: Immortalized autosomal dominant PKD (ADPKD) cells that are heterozygous (WT9-7) and homozygous
(WT-9-12) for a truncating Pkd1 mutation, and immortalized normal human tubular cells (HK-2), were exposed to
NF-κB-inducing agents with or without PDTC. Cell proliferation and apoptosis were assessed by bromodeoxyuridine
assay and Annexin V flow cytometry, respectively. NF-κB activity was assessed by luciferase reporter assay and western
blotting for nuclear p65, p50, and RelB subunits and cytoplasmic phosphorylated-IκBα.
Results: Serum-induced proliferation was similar in all cell lines over 72 h. PDTC demonstrated anti-proliferative effects
that were delayed in ADPKD cells compared to HK-2. Basal NF-κB-dependent luciferase reporter activity was lower in
ADPKD cells compared to normal cells. Classical NF-κB stimulants, lipopolysaccharide (LPS) and tumor necrosis factor
(TNF)-α, increased NF-κB luciferase activity in HK-2, whereas in PKD cell lines, NF-κB activity was only induced by TNF-α.
However, neither stimulant altered proliferation in any cell line. PDTC reduced TNF-α-stimulated NF-κB activity in HK-2
only.
Conclusions: PDTC reduced proliferation in ADPKD cells but did not consistently alter NF-κB activation, suggesting
that other signalling pathways are likely to be involved in its ability to attenuate renal cyst growth in vivo.
Keywords: Nuclear factor-κB (NF-κB), Polycystic kidney disease, Proliferation, Pyrrolidine dithiocarbamate (PDTC), Tumor
necrosis factor (TNF)-α
Background
Polycystic kidney diseases (PKD) are a group of genetically
inherited disorders involving the formation of multiple
renal cysts [1, 2]. Autosomal Dominant PKD (ADPKD)
arises due to mutations in PKD1 and/or PKD2 [3, 4] and
is characterized by the onset of symptoms in adulthood
[2]. In Autosomal Recessive PKD (ARPKD), the mutation
of PKHD1 usually causes lethality during fetal life or in
early childhood [2, 5]. Renal failure is one of the leading
causes of mortality in PKD, and as there are no specific
therapies available, eventually dialysis or renal transplant-
ation is required [1].
The key histological features of PKD are the proliferation
and dedifferentiation of cystic epithelial cells (CECs) ac-
companied by interstitial inflammation and fibrosis [1, 6],
and apoptosis [7–9]. Recent data suggest that the nuclear
factor (NF)-κB system, a key controller of inflammation
and apoptosis [10], is up-regulated in experimental models
of PKD [11, 12]. The use of small interfering RNA to over-
express or deplete the protein products of PKD1 or
PKHD1 in vitro, resulted in up-regulated NF-κB activity
compared to control cells [13, 14]. Increased luciferase NF-
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κB activity and expression of phosphorylated p65 have
been identified in mouse Pkd1−/− cells compared to wild-
type cells [11]. We also previously identified an activated
NF-κB protein, phosphorylated p105, in the CECs of the
Lewis Polycystic Kidney (LPK) rat (a NEK8/NPHP9 ortho-
log phenotypically resembling human ARPKD) [15–17].
Notably, inhibitors of NF-κB modify aberrant apoptosis in
mutant PKD cells [13] and decrease cyst area in Pkd1−/−
mouse kidney explants [11].
Pyrrolidine dithiocarbamate (PDTC) is a well-known
inhibitor of NF-κB activation capable of decreasing the
expression of inflammatory genes, including chemokine
(C-C motif) ligand 2 (CCL2), in rat tubular epithelial and
mesangial cells [18, 19]. PDTC has known anti-
proliferative effects on renal cancer cells [20] and vascular
smooth muscle cells [21]. The compound has demon-
strated divergent effects on apoptosis, increasing apoptosis
in renal cell carcinoma cells [20], but decreasing ischemia-
induced and cadmium-induced apoptosis in renal tubular
cells [22, 23]. We previously demonstrated that in the
LPK rat, chronic administration of PDTC for 7 weeks
attenuated kidney enlargement by 25 %, as determined by
MRI-assessed total kidney volume and kidney weight [16].
This was associated with a reduction in three dimensional
cyst volume but without any changes in interstitial disease
or cell proliferation.
The aim of the current study was to determine if
PDTC alters the proliferation and survival of CECs in
vitro. We utilized HK-2 cells (immortalized cells derived
from proximal tubules of normal human kidney cortex
[24]) and WT9-7 and WT9-12 cells (two immortalized
cell lines originally derived from a human ADPKD kid-
ney [25]). Mutational analysis has found that WT9-7
cells are heterozygous for a truncating PKD1 mutation
(Q2556X), while WT9-12 cells are homozygous for this
mutant allele [26]. The two cell lines are thought to ex-
emplify the “two-hit hypothesis”, which suggests that
while all cells of an ADPKD patient originally possess
one mutated and one normal allele, environmentally ac-
quired injury causes a somatic mutation in the normal
allele, thereby initiating cyst formation [27]. We there-
fore utilized the WT9-7 and WT9-12 cell lines as a
means of comparing the effects of PDTC on PKD cells
that are heterozygous and homozygous for a PKD1 mu-
tation. We hypothesized that PDTC reduces the prolifer-




All cell lines were obtained from the American Type
Culture Collection (ATCC, Manassas, VA) in July 2014.
We utilized HK-2 cells (immortalized cells derived from
proximal tubules of normal human kidney cortex [24],
CRL-2190, Lot no. 61218770, ATCC) and WT9-7 and
WT9-12 cells (two immortalized cell lines originally
derived from a human ADPKD kidney [25], CRL-2830,
Lot no. 58737172, and CRL-2833, Lot no. 60336584,
ATCC). Both PKD cell lines were derived from the same
kidney cortex, however the WT9-7 cells originated from
a non-dilated tubule and possess proximal tubular char-
acteristics, whereas the WT9-12 cells originated from a
dilated (cystic) tubule and have both proximal and distal
characteristics [25]. The WT9-7 cells are heterozygous
for a truncating PKD1 mutation (Q2556X) and possess
the full-length form of polycystin-1 (the gene product of
PKD1), whereas the WT9-12 cells are homozygous for
the Q2556X mutation and express polycystin-1 only in
its truncated form [26]. The WT9-7 and WT9-12 cell
lines were immortalized by transformation with wild
type adeno-simian (SV)40 virus large T antigen [25],
which inhibits p53 activity and mediates the progression
of the cell cycle into the S-phase [28]. The HK-2 cells
were derived from proximal tubular cells of a normal
human kidney [24] and were immortalized by human
papilloma virus (HPV 16) E6 and E7 genes, which inhibit
the pro-apoptotic proteins, p53 and retinoblastoma,
respectively [29]. HK-2 cells were cultured in a 1:1 ratio
of DMEM and F12, 10 % fetal bovine serum (FBS), with
penicillin and streptomycin. WT9 cells were cultured in
DMEM (3.7 g/mL sodium bicarbonate), 10 % FBS, with
penicillin and streptomycin. All cultures were main-
tained at 37 °C, 5 % CO2.
Cell viability assay
For all cell viability and proliferation assays, HK-2 and
WT9-12 cells were seeded at 5 x 103 cells/well in a 96-
well plate, and cultured for 24 h prior to the addition of
PDTC. PDTC (Sigma-Aldrich, St. Louis, MO) was dis-
solved in media and filter-sterilized. For assessment of
viability, cells were incubated with vehicle control, 5 μM,
20 μM, or 50 μM PDTC for 6, 24, or 48 h. At the end of
each timepoint, the MTT assay (11465007001, Roche
Diagnostics, Mannheim, Germany) was performed ac-
cording to manufacturer’s instructions. Absorbance was
measured at 570 nm (reference 750 nm). Cell viability
was calculated by 100 x (Absorbance of Sample/Average
absorbance of untreated control) for the respective
cell line.
Assessment of proliferation
Cell proliferation was assessed using the bromodeox-
yuridine (BrdU) assay (11647229001, Roche) according
to manufacturer’s instructions. In the first series of
experiments, cells were incubated with 20 μM PDTC
for 4, 8 or 24 h. In a separate series of experiments,
lipopolysaccharide (LPS, 10ug/ml, L2630, from E.coli,
Sigma-Aldrich) or tumor necrosis factor-α (TNF-α,
Ta et al. BMC Nephrology  (2015) 16:212 Page 2 of 13
20 ng/ml, human recombinant, #130-094-020, Miltenyi
Biotec, Bergisch Gladbach, Germany) was added to the
cells for 4 h or 24 h. The concentrations of LPS and
TNF-α were based on doses that stimulated NF-κB
activity in HK-2 cells in previous studies [30–32]. Four
hours before the end of each timepoint, BrdU was
added to a final concentration of 10 μM. Absorbance was
measured at 450 nm (reference 620 nm). Cell proliferation
(%) was calculated as 100 x Absorbance/Average absorb-
ance of the vehicle group, of each experiment.
Assessment of apoptosis
Cells were seeded in 100 mm dishes and grown for 24 h.
Cells were then treated with vehicle, 20 μM PDTC,
200 μM PDTC, or 5 μM camptothecin. After 24 h of
treatment, cells were harvested by trypsinization, resus-
pended at 106 cells/ml in 1X Annexin V Binding Buffer
(BD Biosciences, Franklin Lakes, NJ), and 100 μl (105
cells) were added to each FACS tube. Cells were stained
with 7-AAD (5 μl/100 μl, #559925, BD Biosciences, to
assess cell death), and APC-conjugated Annexin V (5 μl/
100 μl, #550474, BD Biosciences, to assess apoptosis) for
15 min and analyzed on BD FACSCantoII. As positive
controls for apoptosis and cell death, cells were incu-
bated for 24 h with 5 μM camptothecin (Sigma-Aldrich)
[33, 34] or 200 μM PDTC, respectively. FACS data were
acquired using FACSDiva (v6.1.3, 2009, BD Biosciences)
and analyzed using FlowJo software (v10.0.7r2, Tree Star,
Ashland, OR) and the percentage of APC+ cells obtained.
Luciferase-reporter NF-κB assay
Cells were seeded at 2 x 105 cells per well in a 6-well plate
and grown for 24 h. Cells were transfected with 0.4 μg/well
of luciferase reporter plasmid 3 ×NF-κB(IC)tk-LUC con-
taining 3 repeating NF-κB promoter sequences [35–37] (a
kind gift of Dr. Scott Read, Storr Liver Unit, The West-
mead Institute for Medical Research , Australia). As a con-
trol for transfection efficiency, cells were co-transfected
with 0.5 μg/well of pEGFP-N1 N-terminal protein fusion
vector containing a human cytomegalovirus (hCMV) pro-
moter (GenBank Accession #U55762, Clontech Laborator-
ies, Palo Alto, CA). Transfection was performed in a final
volume of 1 mL media, 10 % FBS, with a 3 μL:1 μg ratio of
FugeneHD (Promega Corporation, Madison, WI) to plas-
mid. Four hours post-transfection an additional 1 mL of
media was added. Twenty hours post-transfection, the
medium was changed and cells were treated with either ve-
hicle, LPS (10 μg/mL) or TNF-α (20 ng/ml) for a further
4 h. In a separate set of experiments, cells were pre-
incubated with 20 μM PDTC for 1 h prior to incuba-
tion with LPS and TNF-α. Cells were washed with PBS,
lysed using Cell Culture Lysis Reagent (Promega) and
assayed in a Victor plate reader (PerkinElmer, Waltham,
MA) using Luciferase Reagent (Promega) according to
manufacturer’s instructions. Luciferase activity was nor-
malized to GFP fluorescence levels.
Western blot
For western blots, cells were seeded at 1.2×106 cells per
100 mm dish. Twenty hours post-seeding, media was
changed and cells were pre-incubated with 20 μM PDTC
for 1 h, then were treated with vehicle, LPS or TNF-α for a
further 4 h. Cells were trypsinized and nuclear extraction
performed using the NE-PER kit (Thermo Fisher Scientific,
Waltham, MA) according to manufacturer’s instructions.
Nuclear and cytosolic extracts were stored at −80 °C. Pro-
tein concentration of the extracts was assessed using the
DC Protein Assay (Bio-Rad Laboratories, Hercules, CA).
Whole cell lysates were obtained using RIPA buffer
(Thermo Fisher) according to manufacturer’s instructions.
For western blotting, proteins were electrophoresed on 4–
15 % Mini-PROTEAN stain-free TGX gels and semi-dry
transferred to PVDF membranes (Bio-Rad). Membranes
were blocked with 5 % BSA then incubated with antibodies
for toll-like receptor 4 (TLR4, 1:1000, ab22048, Abcam,
Cambridge, UK), p50/105 (1:1000, ab7971, Abcam), p65
(1:1000, #8242, Cell Signaling Technology, Danvers, MA),
RelB (1:1000, #4922, Cell Signaling), β-actin (1:1000,
#4970, Cell Signaling), phosphorylated-IκBα (p-IκBα,
1:1000, #9246, Cell Signaling), IκBα (1:1000, #4814, Cell
Signaling), and GAPDH (1:1000, #5174, Cell Signaling)
overnight at 4 °C. Antibodies against p100 (ab6549,
Abcam) and p52 (#4882, Cell Signaling) were also tested
but yielded no signal by immunoblotting. Secondary anti-
bodies (anti-rabbit IgG, 1:10,000, A0545; anti-mouse,
1:10,000, A6782, Sigma-Aldrich) were applied for 1 h at
room temperature. Blots were developed using SuperSignal
West Pico and Femto chemiluminescent substrates
(Thermo Fisher), and imaged using the Chemidoc MP sys-
tem (Bio-Rad). Densitometry was quantified using ImageJ
(v1.47, National Institutes of Health, USA) and normalized
using β-actin (for nuclear extracts) or GAPDH (for cyto-
plasmic and whole cell extracts). Phosphorylated IκBα was
normalized against total IκBα.
Statistical analyses
Data are expressed as mean ± standard deviation. Statis-
tical analysis was performed using an independent t-test
(or Mann–Whitney U test with non-parametric data-
sets), or one-way or two-way ANOVA as appropriate,
with Bonferroni post-hoc tests. P-values less than 0.05
were considered statistically significant.
Results
Pattern of serum-induced proliferation is similar in HK-2
and ADPKD cells
Serum-induced proliferation was assessed by a time-
course BrdU assay of HK-2, WT9-7 and WT9-12 cells.
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In all three cell lines, an increase in proliferation was
observed over time (Fig. 1)
Onset of anti-proliferative effects of PDTC are delayed in
ADPKD cells compared to HK-2 cells
Prior to assessing the effects of PDTC on serum-induced
proliferation, we firstly assessed the compound’s cytotox-
icity by MTT assay. This revealed a time- and dose-
dependent effect of PDTC on the viability of HK-2,
WT9-7 and WT9-12 cells (Table 1). At 24 h in all cell
lines, viability was significantly decreased in the 50 μM
PDTC group compared to the control. At 48 h, the low-
est tested concentration (5 μM) decreased cell viability.
Since cell viability was not significantly altered using
20 μM PDTC at 24 h (Table 1), this concentration and
incubation period were selected for subsequent experi-
ments. In HK-2 cells, PDTC treatment resulted in sig-
nificant decreases in proliferation compared to untreated
control after 4, 8 and 24 h of incubation (Fig. 2). In
contrast, in WT9-7 cells PDTC significantly reduced
proliferation only after 8 h and 24 h of treatment, and
in WT9-12 cells an anti-proliferative effect was only
observed at the 24 h timepoint.
Flow cytometry for Annexin V found that 24 h incuba-
tion with 20 μM PDTC did not alter apoptosis in any
cell line (p > 0.05, mean ± SD of n = 9 from two experi-
ments, Table 2 and Fig. 3).
TNF-α-induced NF-κB reporter activity is abrogated by
PDTC in HK-2 but not in ADPKD cells
Endogenous NF-κB activity was assessed by luciferase
reporter assay 24 h post-transfection and found to be
lower in ADPKD cells compared with HK-2 cells
(Fig. 4a). In addition, NF-κB activity was lower in WT9-
12 cells compared to WT9-7. Given the low basal levels
of NF-κB activity in ADPKD cells, we sought to deter-
mine the effects of classical NF-κB stimuli, namely LPS
and TNF-α, on NF-κB activity in the three cell lines. In
HK-2 cells, stimulation with LPS (10 μg/ml) for 4 h
resulted in a three-fold increase in NF-κB activity over
Fig. 1 Proliferation of normal and ADPKD cells over a 72 h period. Serum-induced proliferation was assessed by BrdU assay in HK-2, WT9-7 and WT9-12
cells. Cell proliferation is expressed as the fold-change in absorbance over 0 h for the corresponding cell line. Data are expressed as mean ± SD from 2
experiments, with n= 6–8 per treatment group in each experiment. **p < 0.01 vs. 0 h for corresponding cell line
Table 1 Effect of PDTC on the percentage of viable HK-2,
WT9-7 and WT9-12 cells, assessed by MTT assay after 6 h, 24 h
and 48 h of treatment
HK-2 WT9-7 WT9-12
6 h
Control 100 ± 19.0 100 ± 10.2 100 ± 13.9
5 μM 99.6 ± 8.5 110 ± 26.8 103.0 ± 9.8
20 μM 98.8 ± 9.2 120.2 ± 13.1 97.1 ± 7.8
50 μM 76.8 ± 13.5 43.4 ± 9.3 ** 87.6 ± 14.1
24 h
Control 100 ± 15.0 100 ± 8.8 100 ± 12.6
5 μM 105.8 ± 7.7 85.2 ± 20.1 97.8 ± 14.3
20 μM 112.2 ± 7.6 103.6 ± 27.3 99.9 ± 9.1
50 μM 42.7 ± 2.8 ** 17.1 ± 7.7 ** 72.9 ± 5.9 **
48 h
Control 100 ± 9.6 100 ± 13.3 100 ± 5.9
5 μM 76.9 ± 7.1 ** 50.4 ± 11.7 ** 75.9 ± 8.4 **
20 μM 90.3 ± 10.9 91.7 ± 24.0 82.1 ± 8.0 **
50 μM 19.3 ± 2.0 ** 6.0 ± 0.5 ** 51.7 ± 9.2 **
Data are expressed as mean ± SD from n = 8 wells. **p < 0.01 vs. untreated
control for the same cell line at the corresponding timepoint
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vehicle control, while TNF-α (20 ng/ml) caused a 15-fold
increase in NF-κB activity (Fig. 4b). In contrast, LPS failed
to induce a significant increase in luciferase NF-κB activity
in WT9-7 and WT9-12 cells. However, the PKD cells were
responsive to TNF-α, which increased NF-κB activity
three-fold in WT9-7, and 11-fold in WT9-12 cells, over
baseline. Western blotting demonstrated that all cells
expressed TLR4 (a key receptor involved in mediating
LPS-induced NF-κB signaling [38], Fig. 4c), suggesting
that the lack of response to LPS in PKD cells was not due
to an absence of this protein. Incubation of the cells with
20 μM PDTC abated TNF-α-induced NF-κB stimulation
in HK-2 but not in WT9-7 or WT9-12 cells (Fig. 4d).
To confirm the results of the luciferase assay, western
blotting for nuclear NF-κB proteins was performed. In
contrast to the luciferase assay, immunoblotting indi-
cated that basal nuclear expression of p50 and p65 was
comparable between HK-2, WT9-7 and WT9-12 cells
(p50 expression: HK-2, 1.0 ± 0.2; WT9-7, 1.4 ± 1.2; WT9-
12, 0.9 ± 0.2, p > 0.05; p65 expression: HK-2, 1.0 ± 0.1;
WT9-7, 2.2 ± 2.2; WT9-12, 1.2 ± 0.7, p > 0.05, Fig. 5a).
Nuclear levels of p50, p65 and RelB were up-
regulated by 4 h of stimulation with TNF-α in all cell
lines, but were not significantly altered by LPS (Figs. 5b
and 6). PDTC decreased the TNF-α-induced increase of
nuclear p50, but not of nuclear p65 or RelB, although
there was a trend toward a reduction in p65 in HK-2
cells (p = 0.099). Cytoplasmic p-IκBα was increased
with TNF-α stimulation in WT9-7 and WT9-12 cells
but not in HK-2 cells. PDTC did not attenuate the
TNF-α-induced increase in p-IκBα. No changes in IκBα
were detected in any cell lines (p > 0.05, Additional file
1: Table S1).
Classical NF-κB stimulants do not increase proliferation in
either HK-2 or PKD cells
We then verified whether the effects of LPS and TNF-α
on NF-κB activity could be associated with any effects
on proliferation. BrdU assay demonstrated that com-
pared to vehicle control, LPS (10ug/ml) and TNF-α
(20 ng/ml) did not alter proliferation in any of the cell
lines, at either 4 h or 24 h of treatment (Fig. 7).
Discussion
We previously showed that chronic administration of
PDTC to LPK rats decreased renal cyst growth but was
not associated with changes in interstitial inflammation,
fibrosis, cell proliferation or NF-κB activity [16]. How-
ever, since in this model cell proliferation is elevated in
early stages (week 3) compared to later stages of life
(week 12), [39] PDTC may have had early anti-
proliferative effects that were not detectable at the final
timepoint (week 11). Therefore, the primary objective of
the current study was to determine, in vitro, whether in-
hibition of cell proliferation and NF-κB signaling can ex-
plain the cyst-inhibiting properties of PDTC. In addition,
to extend upon our in vivo study which was conducted
in a non-orthologous model of ARPKD, we used WT9-7
and WT9-12 cells, which possess mutated PKD1 allele/s
and truncated polycystin-1 protein, to model cellular
function in ADPKD.
Cyst growth in PKD is associated with excessive prolif-
eration of cyst-lining cells, and can be ameliorated by
anti-proliferative agents [40, 41]. Polycystin-1-depleted
renal cells exhibit accelerated proliferation compared to
Fig. 2 Effect of PDTC on proliferation in normal and ADPKD cells. HK-2, WT9-7 and WT9-12 cells were treated with 20 μM PDTC for 4, 8 and 24 h.
Cell proliferation was calculated as the percentage change in absorbance, over the vehicle-treated group, for each experiment. Data as Mean +
SD from n = 3 experiments. **p = 0.01, ***p < 0.001
Table 2 Percentage of Annexin V positive cells
Control PDTC
HK-2 3.8 ± 1.5 5.2 ± 1.8
WT9-7 10.3 ± 3.9 11.2 ± 5.0
WT9-12 6.5 ± 2.0 7.2 ± 1.1
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Fig. 3 Effect of PDTC on apoptosis in normal and ADPKD cells. Representative FACS plots of Annexin V and 7AAD in HK-2, WT9-7 and
WT9-12 cells
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controls [42, 43], and since WT9-7 and WT9-12 cells
have abnormal polycystin-1 expression [26], we hypothe-
sized that proliferation rates would be higher in WT9
cells than in normal HK-2 cells. Instead, we found that
HK-2, WT9-7 and WT9-12 cells have similar basal pro-
liferation kinetics. This suggests that the PKD1 mutation
in and of itself does not lead to increased cell prolifera-
tion, and therefore extrinsic factors may be responsible.
Our results contrast with those of Aguari et al., which
found increased proliferation rates in WT9-7 and WT9-
12 cells relative to normal 4/5 cells [44]. Notably, the 4/





Fig. 4 NF-κB-dependent luciferase reporter activity and TLR4 expression in normal and ADPKD cells. a Endogenous NF-κB activity in HK-2, WT9-7 and
WT9-12 cells, 24 h post-transfection. **p < 0.01 vs. HK-2, ##p < 0.01 vs. 9–7 cells. Data are expressed as mean + SD from 3 experiments. b NF-κB activity
was stimulated by 4 h of incubation with LPS (10 μg/mL) or TNF-α (20 ng/mL). NF-κB activity is expressed as the fold-change in luciferase/GFP over
untreated control. *p < 0.05 vs. vehicle control for the corresponding cell line, **p < 0.01 vs. vehicle control for the corresponding cell line. Data are
expressed as mean + SD from 3 experiments. c Expression of TLR4 in HK-2, WT9-7 and WT9-12 cells, determined by western blotting in whole cell
lysates. d PDTC decreased TNF-α-induced NF-κB activity in HK-2 but not in WT9-7 or WT9-12 cells. Data are expressed as mean + SD from 2
experiments. **p < 0.01 vs. vehicle control for the corresponding cell line; ##p < 0.01
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the same method as were the WT9-7 and WT9-12 cells
(i.e. SV40 T antigen) [28, 44], whereas our control cell line,
HK-2, was transformed by HPV16 E6/E7 [24]. Although
we are not aware of any comparative studies of prolifera-
tion between these vectors, it is conceivable that
immortalization may have altered the basal proliferative
properties of the cell lines used.
The current study showed that PDTC reduced prolifera-
tion in ADPKD cells. This contrasts with our study in
LPK rats, in which chronic PDTC administration dimin-
ished cyst growth without decreasing Ki67-positive cell
proliferation [16], and may suggest that PDTC has imme-
diate rather than long-term anti-proliferative effects. Inter-
estingly, the anti-proliferative effects of PDTC occurred
earlier in HK-2 compared to PKD cells. This may suggest
that the PKD1 mutation confers some resistance to the
anti-proliferative effects of PDTC. The anti-proliferative
effects of PDTC in HK-2 cells could be viewed as harmful
for the healthy cell population in renal disease. However,
it is worth noting that in our study, cells were cultured in
sub-confluent conditions, which differ to the healthy kid-
ney. Furthermore, it is known that susceptibility to drug
cytotoxicity is decreased in cells grown at higher compared
to lower densities [45, 46]. Therefore PDTC may not neces-
sarily be detrimental under physiological conditions, in
which the complete cell-cell contacts may confer some
protection against the drug’s anti-proliferative effects.
There is evidence that the NF-κB system is up-regulated
in experimental models of PKD [11, 12]. However, in our
study, immunoblotting suggested that endogenous p50
and p65 levels were comparable between normal and PKD
cells, and luciferase assay data indicated that basal NF-κB
activity was in fact lower in PKD cells compared to nor-
mal cells. It is worth noting that whereas the luciferase
assay measures DNA-binding activity of NF-κB proteins,
immunoblotting only assesses the quantity of nuclear NF-
κB proteins, and this may explain the differences between
the results obtained by these two techniques. Our findings
differ to those of Aguari et al., which demonstrate that
NF-κB nuclear translocation is elevated in WT9-7 and
WT9-12 compared to 4/5 cells [44]. The differences
between our findings may be explained by the use of dif-
fering NF-κB plasmids and immortalization techniques
(as discussed above). It is also possible that the
immortalization process itself can modulate basal NF-
κB activity, and therefore future studies could verify
this result by examining basal NF-κB activity in pri-
mary ADPKD cells.
We also sought to investigate the effects of classical
NF-κB stimuli in immortalized ADPKD cells. Tumor ne-
crosis factor-α directly induces cystogenesis in kidney ex-
plants [47] and regulates its own transcription via NF-κB
in murine PKD cells [48, 49]. Our study found TNF-α to
be a potent inducer of NF-κB in both normal and ADPKD
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Fig. 5 Expression of NF-κB proteins in nuclear extracts from normal and ADPKD cells. a Endogenous nuclear p50 and p65 expression. Representative
blots from n = 3 experiments. b Representative western blots demonstrating the effects of LPS, TNF-α and PDTC on nuclear NF-κB p50, p65 and RelB,
and cytosolic p-IκB levels
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cells, concurring with previous data from transformed
cells overexpressing polycystin-1 [14]. In addition, we ob-
served stimulus-specific induction of NF-κB in ADPKD
cells, whereby both LPS and TNF-α up-regulated lucifer-
ase reporter NF-κB activity in HK-2 cells, while only TNF-
α significantly up-regulated NF-κB in WT9 cells. Both
LPS and TNF-α have been consistently identified in
ADPKD cyst fluid [47, 50–52], thus it is unlikely that the
lack of response to LPS is related to the availability of LPS
in the cyst lumen. Since the lack of LPS-induced NF-κB
stimulation is not due to an absence of TLR4 (a key recep-
tor in the LPS-stimulated pro-inflammatory pathway
[38]), other possible explanations for the discrepancy
include defects in TLR4 or other proteins necessary for
LPS binding, or differences in downstream signaling path-
ways. The discrepancy may also reflect differing roles of
Fig. 6 Densitometry quantification of western blot data. Data are expressed as mean + SD from n= 3 experiments. **p< 0.01 vs. vehicle-treated control;
#p< 0.05; ##p<0.01
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LPS and TNF-α in PKD etiology; TNF-α is known to in-
duce cystogenesis in vivo [47], while it is unclear whether
LPS can independently stimulate cyst growth in PKD
[51, 53, 54]. Although LPS and TNF-α have previously
been found to increase proliferation of renal cells in vitro
[55, 56], neither stimulus altered proliferation in human
PKD cells in this study, suggesting that the effects of these
agents on NF-κB activation were not mediated through
changes in cellular growth.
PDTC inhibits NF-κB activity by preventing proteasomal
degradation of IκB, thereby retaining NF-κB proteins in
the cytoplasm and obstructing their translocation to the
nucleus [57]. PDTC decreased TNF-α-induced NF-κB lu-
ciferase reporter activity in HK-2 cells but not in WT9
cells, indicating that compared to normal cells, ADPKD
cells may be less susceptible to NF-κB inhibition. In agree-
ment with this, PDTC did not attenuate TNF-α-induced
elevations in nuclear p65 or RelB or cytoplasmic p-IκBα,
although it did decrease nuclear p50 expression in all cell
lines. Notably, immunoblotting was performed on extracts
obtained at a single timepoint (4 h following stimulation by
LPS or TNF-α), whilst the luciferase assay measured
Fig. 7 Effects of LPS and TNF-α on proliferation of normal and ADPKD cells. BrdU assay was performed in a HK-2, b WT9-7 and c WT9-12 cells
following 4 h and 24 h of treatment with LPS (10 μg/ml) or TNF-α (20 ng/ml). Cell proliferation is expressed as the fold-change in absorbance
over 0 h for the corresponding cell line. Data as mean + SD of n = 12 wells from 3 experiments
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cumulative NF-κB activity over the entire treatment period.
Thus, nuclear p65 and RelB levels may have rapidly de-
creased early within the treatment period and restabilized
by 4 h, whilst nuclear p50 levels may have decreased more
steadily over time. It is known that p50 and p65 differ in
their susceptibility to inhibition by IκB [58, 59], and par-
ticular IκB proteins inhibit certain dimer combinations
more selectively than others (e.g. IκBα preferentially binds
p65:p50 dimers over p65 homodimers) [60]. The reduction
by PDTC in nuclear p50 but not p65 and RelB, may sug-
gest that PDTC is more effective at preventing degradation
of IκB proteins associated with p50, than of those binding
the other NF-κB proteins. Given that p50 is structurally
different to p65 and RelB (which possess transactivation
domains), and that p50 homodimers can in fact repress
transcription [10], future studies would benefit from char-
acterizing the subunit composition of NF-κB complexes
inhibited by PDTC.
In this study we used WT9-7 and WT9-12 cells, which
are respectively heterozygous and homozygous for a
PKD1 mutant allele. Full-length polycystin-1 (the gene
product of PKD1) is present in WT9-7 but not in WT9-
12 cells [26]. Within the “two-hit hypothesis” of ADPKD
(which proposes that for cystogenesis to occur, a cell must
possess both an inherited germline and a somatically ac-
quired PKD1/2 mutation [61]), WT9-7 cells represent
those cells possessing only the germline mutation, while
WT9-12 cells represent those having acquired a second
somatic hit. The hypothesis proposes that following the
second somatic mutation, cells enter a hyperproliferative
state and expand clonally [26, 61]. Whilst we did not find
a difference in basal proliferation between WT9-7 and
WT9-12 cells, the delayed anti-proliferative effect of
PDTC on WT9-12 compared to WT9-7, might support
the notion that loss of heterozygosity confers abnormal
proliferative properties.
More recently, the “gene dosage” hypothesis has pro-
posed that a second somatic mutation is not prerequisite
for cystogenesis, but rather that cystogenesis commences
if the amount of functional polycystin varies outside a
certain range [27, 62, 63]. Compared to normal cells,
WT9-7 cells are more resistant to the anti-proliferative
and NF-κB-inhibiting properties of PDTC, and respond
abnormally to fluid-shear stress [26]. Although it is pos-
sible that there is an undetected somatic mutation in
WT9-7 cells [26], these observations may imply that
levels of full-length polycystin-1 in WT9-7 cells are
below the necessary “dosage” for normal cellular func-
tion [26]. Furthermore, compared to WT9-7 cells, WT9-
12 cells had a delayed response to the anti-proliferative
effects of PDTC (24 h vs. 8 h), and had lower basal NF-
κB activity but a higher fold-increase in NF-κB following
TNF-α stimulation. These data suggest that abnormal-
ities in proliferation and NF-κB signaling may be corre-
lated to the amount of full-length polycystin-1 expressed
by a cell, although further studies are required to verify
this trend and determine whether a causal relationship
exists.
There were some limitations to this study. PDTC has
pleiotropic properties including DNA damage [64, 65],
anti-oxidant effects [66] and gene modulation [67],
which were not examined in this study. Importantly,
the results observed in WT9 cells do not necessarily
explain the effects of PDTC in LPK rats, since the
two models have dissimilar genetic mutations (PKD1
vs. NEK8) [17, 25], and due to intrinsic differences
between in vitro and in vivo models. Furthermore, the
WT9 cells, which grow as a monolayer, cannot repli-
cate the trans-epithelial fluid and ion transport
processes that occur in three-dimensional renal cysts.
Future studies could utilize collagen matrix cyst models
to investigate whether PDTC inhibits cyst growth in vitro,
and thereby determine whether TNF-α-induced cystogen-
esis is dependent on NF-κB [47]. Finally, the effects of the
NF-κB stimuli were observed at single concentrations,
and further work could verify whether varying concentra-
tions of LPS and TNF-α differentially modify NF-κB
activation in PKD cells.
Table 3 Summary of the main findings of this study
HK-2 WT9-7 WT9-12
Pattern of serum-induced proliferation Increased in a time-dependent
manner
Same pattern as HK-2
cells
Same pattern as HK-2
cells
Effect of PDTC on proliferation Reduced at 4-24 h Reduced at 8-24 h Reduced at 24 h
Endogenous NF-κB reporter activity High Moderate Low
Effect of exogenous LPS on NF-κB reporter activity Increased No change No change
Effect of exogenous TNF-α on NF-κB reporter activity Increased Increased Increased
Effect of PDTC on TNF-α-induced NF-κB reporter activity Reduced No change No change
Effect of PDTC on TNF-α-induced nuclear NF-κB protein
levels
Reduced p50 Reduced p50 Reduced p50
Effect of exogenous LPS and TNF-α on proliferation at 4 h
and 24 h
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Conclusions
This study found that PDTC decreases the proliferation
of immortalized human ADPKD cells, suggesting that
this may be the mechanism of action by which the com-
pound decreases cyst growth in experimental PKD [16].
Anti-proliferative effects of PDTC were delayed in
ADPKD cells compared to normal cells. PDTC reduced
TNF-α-stimulated NF-κB activity in HK-2 but not in
ADPKD cells. Hence, in HK-2 cells there was an associ-
ation between the reduction of proliferation and NF-κB
activity, but no such association was observed in
ADPKD cells (Table 3). Overall, this suggests that NF-κB
functionality may be less critical for growth in ADPKD
cells than in normal cells. It is worth noting that this
study only identified an association between the effects
of PDTC on proliferation and NF-κB activity, and further
work is required to verify whether NF-κB-dependent pro-
liferation is dysregulated in ADPKD cells. Future studies
should also examine whether NF-κB stimulation can dir-
ectly instigate cystogenesis and whether specific NF-κB
inhibition is a viable strategy to abrogate cyst expansion in
PKD.
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